Method of treating an autoimmune disorder

• US 6,274,612 B1
• Filed: 05/31/2000
• Issued: 08/14/2001
• Est. Priority Date: 06/19/1998
• Status: Expired due to Fees

• Current Assignee: Thomas B. Bryan
• Original Assignee: Thomas B. Bryan
• Inventors: Bryan, Thomas B.
• Primary Examiner(s): HENLEY III, RAYMOND J
• Application Number:
  US09/585,245
• Time in Patent Office: 440 Days
• Field of Search: 514/400, 514/561, 514/562, 514/565
• US Class Current: 514/400
• CPC Class Codes: A61K 31/195 having an amino group
• CPC Class Codes: A61K 31/197 the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid carnitine A61K31/205
• CPC Class Codes: A61K 31/198 Alpha-amino acids, e.g. alanine or edetic acid [EDTA] betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00
• CPC Class Codes: A61K 31/401 Proline; Derivatives thereof, e.g. captopril
• CPC Class Codes: A61K 31/405 Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
• CPC Class Codes: A61K 31/415 1,2-Diazoles
• CPC Class Codes: A61K 31/4172 Imidazole-alkanecarboxylic acids, e.g. histidine
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 21/04 for myasthenia gravis
• CPC Class Codes: A61P 25/02 for peripheral neuropathies

Abstract

A method of administering an amino acid protocol intravenously for the treatment of a patient suffering from an autoimmune disease is provided.

Claims

1. A method of treating an autoimmune disease in a patient suffering therefrom, the method comprising:

intravenously administering an amino acid protocol to said patent, said patient capable of being orally or gastrically nourished, said patient suffering from an autoimmune disease selected from the group consisting of Myasthenia Gravis, Guillain-Barr like syndrome, Behcet'"'"'s disease, Thyroiditis, cerebral vaculitis, post-infusion purpura, chronic inflammatory demyelinating polyneuropathy, Sjogren'"'"'s syndrome, ticks and obsessive-compulsive disorder triggered by infection, stiff-man syndrome, Eaton-Lambert syndrome, Goodpasture syndrome, dermatomyositis, polymyositis, thrombocytopenia, warm type autoimmune hemolytic anemia, systemic vasculitic syndromes, West syndrome, Lennox-Gastaut syndrome, acute renal failure, asthma, chronic fatigue syndrome, diabetes mellitus, inclusion body myositis, rheumatoid arthritis, recurrent spontaneous abortion, euthyroid ophthalmopathy, and immune mediated neutropenia.

2. The method of claim 1, wherein said amino acid protocol comprises at least one essential amino acid.

3. The method of claim 2, wherein said amino acid protocol comprises at least one of Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan and Valine.

4. The method of claim 1, wherein said amino acid protocol comprises at least one non-essential amino acid.

5. The method of claim 4, wherein said amino acid protocol comprises at least one of Alanine, Arginine, Histidine, Proline, Serine, Glycine and Cystein.

6. The method of claim 1, wherein said amino acid protocol comprises at least one of Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine, Alanine, Arginine, Histidine, Proline, Serine, Glycine and Cystein.

7. The method of claim 1, wherein said amino acid protocol comprises an essential amino acid, a non-essential amino acid, a glycerin, an electrolyte and a vitamin.

8. The method of claim 1, wherein the patient is administered the amino acid protocol until the autoimmune disease abates.